container

Early Detection of Exfoliative Glaucoma (XFG) Now Possible With Use of Visual Evoked Potential (VEP)

Diopsys® NOVA-VEP data shows new hope for patients with degenerative eye diseases.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
Diopsys NOVA-VEP
The Diopsys® NOVA-VEP Vision Testing System used to record the results and was able to detect significant differences between unilateral XFS/XFG and normal eyes which could lead to earlier detection and treatment of XFG and better outcomes for patients.

Pine Brook, NJ (PRWEB) May 30, 2014

Affecting an estimated 60 to 70 million people worldwide, Exfoliation syndrome (XFS) is the most common identifiable cause of open-angle glaucoma. XFS presents unilaterally in about two thirds of patients and are more likely to present with glaucomatous damage than eyes without XFS. More severe than primary open angle glaucoma (POAG), Exfoliative Glaucoma (XFG) patients experience greater intraocular pressures (IOP), visual field loss, poorer response to medications and are at an increased risk for surgery.

In a recent study, a team of researchers from New York Eye and Ear infirmary compared normal eyes to those affected by unilateral XFS and exfoliative glaucoma (XFG) using Short Duration Transient Visual Evoke Potentials (SD-tVEP). The Diopsys® NOVA-VEP Vision Testing System used to record the results and was able to detect significant differences between unilateral XFS/XFG and normal eyes which could lead to earlier detection and treatment of XFG and better outcomes for patients.

The results of this important study were presented at this year's Association for Research in Vision and Ophthalmology (ARVO), in a poster titled 'Evaluation of the Unaffected Fellow Eye of Unilateral Exfoliation Syndrome and Exfoliative Glaucoma Eyes using Short Duration Transient Visual Evoked Potentials (SD-tVEP)'.

The Diopsys® NOVA Vision Testing system provides objective, functional data about the entire visual pathway from the retina to the visual cortex. Visual Evoked Potential (VEP) test results can help improve sensitivity and specificity in diagnosing visual pathway disorders when used in conjunction with other diagnostic tests.

About Diopsys

Diopsys, Inc. (http://www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing equipment utilizing clinical electrophysiology, including Visual Evoked Potential and pattern Electroretinography.

Diopsys has developed and markets the patented Diopsys® NOVA-VEP and Diopsys® NOVA-ERG Vision Testing Systems utilized by optometrists and ophthalmologists to help in the detection, diagnosis and treatment of vision disorders, including glaucoma and macular degeneration. Diopsys also provides the Enfant® Pediatric VEP Vision Testing System, a device used in testing for visual deficits, including amblyopia, in children as young as six months of age.